InauguralInvitation Only
Psoriasis
USFocus Meeting 2027
Two days, 48 people, one room.
September 10 to 11, 2027
Boston, MA
Dates
September 10-11, 2027
Two-day program
Venue
Boston, MA
Venue TBC
Audience
48 by invitation
24 KOLs & 24 fellows
Format
8 sessions · 24 talks
Expert talks + moderated panels
A Curated Room: The People Shaping Practice
This inaugural, invitation-only meeting convenes a deliberately small faculty: 24 leading psoriatic disease KOLs alongside 24 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.
The science tracks where treatment is moving: biologic and oral selection across mechanisms, nonsteroidal topicals for high-impact sites, psoriatic arthritis interception, cardiometabolic risk in the dermatology clinic, and disease modification. Every session pairs expert talks with a moderated panel, sustained, close-quarters engagement rather than a lecture hall.
Biologics & Oral TherapiesIL-23 · IL-17 · TYK2Psoriatic ArthritisDisease ModificationNonsteroidal TopicalsCardiometabolic Risk · GPP
Meeting Co-Chairs
Listed alphabetically by surname

Jeffrey Cohen
Yale School of Medicine, New Haven, CT

Scott Elman
University of Miami Miller School of Medicine, Miami, FL
Faculty Drawn From
Yale · Mount Sinai · Penn · NYU Langone · Brigham and Women’s · The Rockefeller University and other leading US dermatology centers
48
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
21
Established meetings across the US and Europe, a proven platform
Psoriasis US Focus Meeting 2027
Confirmed Faculty
Listed alphabetically by surname
Andrew Blauvelt
Blauvelt Consulting LLC, Lake Oswego, OR
Christopher Bunick
Yale School of Medicine, New Haven, CT
Gabriela Cobos
Tufts Medical Center, Boston, MA
Jeffrey Cohen
Yale School of Medicine, New Haven, CT
William Damsky
Yale School of Medicine, New Haven, CT
Scott Elman
University of Miami Miller School of Medicine, Miami, FL
Steven Feldman
Wake Forest School of Medicine, Winston-Salem, NC
Michael S. Garshick
NYU Langone Health, New York, NY
Joel Gelfand
University of Pennsylvania, Philadelphia, PA
Linda Stein Gold
Henry Ford Health, Detroit, MI
Kenneth Gordon
Medical College of Wisconsin, Wauwatosa, WI
Rebecca Haberman
NYU Langone Health, New York, NY
Leon Kircik
Icahn School of Medicine at Mount Sinai, New York, NY
Wilson Liao
University of California San Francisco, San Francisco, CA
Arash Mostaghimi
Brigham and Women's Hospital, Boston, MA
Mio Nakamura
University of Michigan, Ann Arbor, MI
Andrea Neimann
NYU Langone Health, New York, NY
Alexis Ogdie
University of Pennsylvania, Philadelphia, PA
Christopher Ritchlin
University of Rochester Medical Center, Rochester, NY
Mona Shahriari
Central Connecticut Dermatology, Cromwell, CT
Eingun James Song
Frontier Dermatology, Mill Creek, WA
Further faculty to be announced
Two Days, Eight Sessions
Proposed Agenda
Presentations15 min
Panel Discussions30 min
Lunch50 min
Day One · Friday, September 10, 2027
Session IInjectable Biologics for PsO
Moderator
Overview of Biologics
Andrea NeimannNYU Langone Health, New York, NY
Biologic Selection
Wilson LiaoUniversity of California San Francisco, San Francisco, CA
Pipeline
Andrew BlauveltBlauvelt Consulting LLC, Lake Oswego, OR
Session IIOral Therapies for PsO
Moderator
Overview of Oral Therapies
Linda Stein GoldHenry Ford Health, Detroit, MI
Selecting an Oral Therapy
Christopher BunickYale School of Medicine, New Haven, CT
Pipeline
Mio NakamuraUniversity of Michigan, Ann Arbor, MI
Session IIITopical Therapies for PsO
Moderator
Overview of Topical Therapies
Mona ShahriariCentral Connecticut Dermatology, Cromwell, CT
Topicals for High-Impact Sites: Genital, Intertriginous, Scalp & Face
Leon KircikIcahn School of Medicine at Mount Sinai, New York, NY
Adherence, Vehicle & Why Topicals Fail in the Real World
Steven FeldmanWake Forest School of Medicine, Winston-Salem, NC
Session IVPsoriatic Arthritis (PsA)
Moderator
Overview of Therapy
Christopher RitchlinUniversity of Rochester Medical Center, Rochester, NY
Future Therapy
Alexis OgdieUniversity of Pennsylvania, Philadelphia, PA
Prevention of PsA
Rebecca HabermanNYU Langone Health, New York, NY
Day Two · Saturday, September 11, 2027
Session VMetabolic Aspects of PsO
Moderator
Cardiovascular Disease in PsO: Overview
Michael S. GarshickNYU Langone Health, New York, NY
GLP-1s for Psoriatic Disease
Scott ElmanUniversity of Miami Miller School of Medicine, Miami, FL
Cardiovascular Disease Prevention in the Dermatology Clinic
Joel GelfandUniversity of Pennsylvania, Philadelphia, PA
Session VIHigh-Impact Sites / Other Treatment Considerations
Moderator
High-Impact Site Psoriasis
Jeffrey CohenYale School of Medicine, New Haven, CT
Pediatric Psoriasis
Speaker TBC
Special Populations: Pregnancy & Chronic Infection
Eingun James SongFrontier Dermatology, Mill Creek, WA
Session VIIDisease Modification and the Treatment Window
Moderator
Inflammatory Memory: Why the Plaque Returns in the Same Place
Speaker TBC
Early Intervention and the Window of Opportunity: Cohort & Registry Data
Speaker TBC
Drug Withdrawal, Tapering & Dose Spacing: Who Can Stop and Who Cannot
Kenneth GordonMedical College of Wisconsin, Wauwatosa, WI
Session VIIISpecial Topics in Psoriatic Disease
Moderator
Personalized Medicine for PsO
William DamskyYale School of Medicine, New Haven, CT
Access, Cost & Care Delivery in Psoriatic Disease
Gabriela CobosTufts Medical Center, Boston, MA
Generalized Pustular Psoriasis (GPP)
Arash MostaghimiBrigham and Women’s Hospital, Boston, MA
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →

Your Point of Contact
Killian Wyness
Account Executive, MD Education
killian.wyness@md-education.com
